Pepgen Inc. (PEPG) — SEC Filings
Pepgen Inc. (PEPG) — 46 SEC filings. Latest: 8-K (Dec 8, 2025). Includes 26 8-K, 6 10-Q, 3 SC 13G.
Overview
Pepgen Inc. (PEPG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: PepGen Inc. reported a net loss of $71.3 million for the nine months ended September 30, 2025, an increase from a net loss of $67.7 million for the same period in 2024. Research and development expenses remained relatively stable at $57.2 million in 2025 compared to $57.5 million in 2024, despite th
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 43 neutral. The dominant filing sentiment for Pepgen Inc. is neutral.
Filing Type Overview
Pepgen Inc. (PEPG) has filed 26 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G, 3 SC 13G/A, 1 DEFA14A, 1 10-K/A, 2 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of PEPG's 34 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$71,315,000 |
| EPS | -$2.14 |
| Debt-to-Equity | 0.16 |
| Cash Position | $142,775,000 |
| Operating Margin | N/A |
| Total Assets | $190,057,000 |
| Total Debt | $26,917,000 |
Key Executives
- Dr. James R. Muldoon
- Dr. David E. R. Sutherland
- Ms. Sarah K. Boyce
- James McArthur
- Noel Donnelly
- Paul Streck
- Dr. Michael J. Yauch
- Dr. Michael J. Yaszemski
- Michael J. Yaszemski
- James R. Rose
- Steven M. Deitcher
- Dr. James McArthur
- Dr. Michelle Mellion
- Peter Kolchinsky
Industry Context
PepGen operates in the biotechnology sector, focusing on developing therapies for rare neuromuscular diseases. This industry is characterized by high R&D costs, long development timelines, significant regulatory hurdles, and a high rate of failure. Success is often dependent on a few key drug candidates, making pipeline concentration a common risk.
Top Tags
sec-filing (6) · financials (6) · regulatory-filing (5) · 8-K (5) · disclosure (4) · corporate-governance (4) · 10-Q (4) · 8-k (3) · filing (3) · financial-statements (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $71.3M | Increased from $67.7M in prior year period, indicating continued operational losses. |
| Cash and Cash Equivalents | $142.8M | Significant increase from $49.4M at year-end 2024, primarily due to a public offering. |
| Public Offering Proceeds | $107.6M | Net capital raised, crucial for funding ongoing operations and PGN-EDODM1 development. |
| Research and Development Expenses | $57.2M | Stable year-over-year despite program discontinuation, reflecting ongoing investment in PGN-EDODM1. |
| Common Stock Outstanding | 68,748,224 | As of November 5, 2025, significantly increased due to the public offering. |
| Commission File Number | 001-41374 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 85-3819886 | Tax identification number for the company. |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating no commercial products |
| General and Administrative Expenses | $6.0M | for the three months ended June 30, 2025, up from $5.2 million in 2024, due to personnel costs |
| Cash, Cash Equivalents, and Marketable Securities | $209.7M | as of June 30, 2025, a decrease from $268.9 million at December 31, 2024 |
| Decrease in Cash, Cash Equivalents, and Marketable Securities | $59.2M | over the six months ended June 30, 2025, highlighting cash burn |
| Reporting Period | Q1 2025 | Financial activities for the first quarter of 2025 are detailed. |
| As of Date | March 31, 2025 | Key balance sheet information is presented as of this date. |
| Key Event Date | February 2024 | Significant financing events like the Shares Sales Agreement and Follow-On Offering occurred. |
| SEC File Number | 001-41374 | Identifies the company's filing history with the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Pepgen Inc. (PEPG)?
Pepgen Inc. has 46 recent SEC filings from Jan 2024 to Dec 2025, including 26 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PEPG filings?
Across 46 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 43 neutral. The dominant sentiment is neutral.
Where can I find Pepgen Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pepgen Inc. (PEPG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pepgen Inc.?
Key financial highlights from Pepgen Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PEPG?
The investment thesis for PEPG includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pepgen Inc.?
Key executives identified across Pepgen Inc.'s filings include Dr. James R. Muldoon, Dr. David E. R. Sutherland, Ms. Sarah K. Boyce, James McArthur, Noel Donnelly and 9 others.
What are the main risk factors for Pepgen Inc. stock?
Of PEPG's 34 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Pepgen Inc.?
Forward guidance and predictions for Pepgen Inc. are extracted from SEC filings as they are enriched.